This article has Open Peer Review reports available.
Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi
© Kadhiravan et al; licensee BioMed Central Ltd. 2005
Received: 23 October 2004
Accepted: 18 May 2005
Published: 18 May 2005
Widespread use of fluoroquinolones has resulted in emergence of Salmonella typhi strains with decreased susceptibility to fluoroquinolones. These strains are identifiable by their nalidixic acid-resistance. We studied the impact of infection with nalidixic acid-resistant S. typhi (NARST) on clinical outcomes in patients with bacteriologically-confirmed typhoid fever.
Clinical and laboratory features, fever clearance time and complications were prospectively studied in patients with blood culture-proven typhoid fever, treated at a tertiary care hospital in north India, during the period from November 2001 to October 2003. Susceptibility to amoxycillin, co-trimoxazole, chloramphenicol, ciprofloxacin and ceftriaxone were tested by disc diffusion method. Minimum inhibitory concentrations (MIC) of ciprofloxacin and ceftriaxone were determined by E-test method.
During a two-year period, 60 patients (age [mean ± SD]: 15 ± 9 years; males: 40 [67%]) were studied. All isolates were sensitive to ciprofloxacin and ceftriaxone by disc diffusion and MIC breakpoints. However, 11 patients had clinical failure of fluoroquinolone therapy. Infections with NARST isolates (47 [78%]) were significantly associated with longer duration of fever at presentation (median [IQR] 10 [7-15] vs. 4 [3-6] days; P = 0.000), higher frequency of hepatomegaly (57% vs. 15%; P = 0.021), higher levels of aspartate aminotransferase (121 [66–235] vs. 73 [44–119] IU/L; P = 0.033), and increased MIC of ciprofloxacin (0.37 ± 0.21 vs. 0.17 ± 0.14 μg/mL; P = 0.005), as compared to infections with nalidixic acid-susceptible isolates. All 11 patients with complications were infected with NARST isolates. Total duration of illness was significantly longer in patients who developed complications than in patients who did not (22 [14.8–32] vs. 12 [9.3–20.3] days; P = 0.011). Duration of prior antibiotic intake had a strong positive correlation with the duration of fever at presentation (r = 0.61; P = 0.000) as well as the total duration of illness (r = 0.53; P = 0.000).
Typhoid fever caused by NARST infection is associated with poor clinical outcomes, probably due to delay in initiating appropriate antibiotic therapy. Fluoroquinolone breakpoints for S. typhi need to be redefined and fluoroquinolones should no longer be used as first-line therapy, if the prevalence of NARST is high.
Typhoid fever is a common illness in developing countries like India  and is a potential threat to developed nations, in an era of increasing air travel and global operations . In the absence of appropriate chemotherapy, typhoid fever was often a fatal illness and introduction of effective antibiotic therapy in 1950s led to a sharp decline in the rates of complications and mortality due to typhoid fever . However, in early 1990s multidrug-resistant strains of Salmonella enterica serotype typhi (MDR-ST) that were resistant to all the three first-line drugs then in use, namely chloramphenicol, amoxycillin and co-trimoxazole emerged, and sooner MDR-ST became endemic in many areas of Asia, including India . This change in pattern of susceptibility was reflected even in places far away, such as the United Kingdom  and the United States of America . Fluoroquinolones are very effective against MDR-ST, achieving fever clearance in less than four days with cure rates exceeding 96%, and are currently the first-line drug for the treatment of typhoid fever .
However, towards the end of the last decade, it was observed that fever took longer time than before to clear, and at times surprisingly failed to respond to ciprofloxacin therapy [8–10]. These isolates had comparatively higher minimal inhibitory concentrations (MIC) of fluoroquinolones, although they were susceptible to fluoroquinolones by conventional disc diffusion testing and recommended MIC breakpoints [8–10]. Nevertheless, such strains of S. typhi are resistant to nalidixic acid and it was noted that clinical response to fluoroquinolones in patients infected with nalidixic acid-resistant S. typhi (NARST) was inferior to the response in those infected with nalidixic acid-sensitive S. typhi (NASST) strains . However, it is not clear whether fluoroquinolones can still be used as first-line drug for the treatment of typhoid fever, and if used whether this has any adverse impact on clinical outcomes other than treatment failure such as development of complications and morbidity assessed in terms of total duration of illness. In this scenario, the present study was undertaken to evaluate the impact of infection with NARST on clinical outcomes in patients with typhoid fever.
This study was conducted at the All India Institute of Medical Sciences (A.I.I.M.S.) hospital, New Delhi, India. This is a tertiary level medical centre located in north India, serving predominantly to low and middle-income groups of the population. All consecutive patients including children with blood culture-proven typhoid fever, admitted to the A.I.I.M.S. hospital during the period November 2001 through October 2003, and those treated as outpatients during this period and were available for at least one follow-up visit, were prospectively included in the study. Patients were evaluated as per a pre-designed instrument, regarding the demographic details, presenting symptoms, physical and laboratory findings and complications. Response to treatment was assessed in terms of fever clearance time.
All isolates from blood culture were identified by standard biochemical tests and confirmed by slide agglutination test using specific Salmonella antiserum (Murex Diagnostics Ltd., UK). Antibiotic susceptibility of the isolates was determined by disc diffusion method using 5 μg disc of ciprofloxacin and 30 μg disc of nalidixic acid (HiMedia Laboratories Ltd., India), as per the National Committee for Clinical Laboratory Standards (NCCLS) guidelines and interpretive criteria . The isolates were also tested for susceptibility to chloramphenicol (30 μg), amoxycillin (10 μg), co-trimoxazole (1.25/23.75 μg) and ceftriaxone (30 μg) (HiMedia Laboratories Ltd., India) by disc diffusion method . Minimum inhibitory concentrations (MIC) of ciprofloxacin and ceftriaxone were determined by the E-test method, using commercially available strips (AB Biodisk, Sweden), as per manufacturer's specifications.
A case of typhoid fever was defined as one that presented with a febrile illness, whose blood culture yielded S. typhi. Susceptibility break points to various antibiotics tested, were taken as per NCCLS definitions . Anaemia was defined as haemoglobin less than 100 g/L. Leucopenia was defined as total leucocyte count less than 4 × 109 cells/L and thrombocytopenia as platelet count less than 100 × 109platelets/L. Leucocytosis was defined as total leucocyte count more than 11 × 109 cells/L. Liver enzymes were considered as elevated if the levels were more than two times the upper limit of normal (cut-off of 100 IU/L for both alanine aminotransferase and aspartate aminotransferase; 560 IU/L for alkaline phosphatase). Fever clearance time was defined as the time from the start of appropriate antibiotic therapy to the first instance, when oral temperature fell to 37.5°C and remained below that level continuously for 48 hours. Clinical failure of fluoroquinolone therapy was defined as continuing fever, even after five days of continuous treatment with a fluoroquinolone.
Treatment of typhoid fever
The choice of antibiotic therapy was at the discretion of the treating physician. The practice in general, was to prescribe oral ciprofloxacin (adults: 500 mg b.i.d.; children: 15 mg/kg/day) or ofloxacin (adults: 400 mg b.i.d.; children: 15 mg/kg/day) or cefixime (20 mg/kg/day) for outpatient treatment and to admit the patient for in-patient care, if felt by the treating physician to be not responding to therapy or acutely ill. Hospitalised patients received parenteral antibiotic therapy, either ceftriaxone (adults: 2 g b.i.d.; children: 75 mg/kg/day) or a fluoroquinolone or a combination regimen, as decided by the treating physician.
All statistical analyses were done using a software package (SPSS for Windows, Version 10.0.1, SPSS Inc., Chicago, IL). Continuous variables are presented as mean ± standard deviation (SD) or as median with interquartile range (IQR). Categorical variables are expressed as proportions. Independent sample t test or Mann-Whitney U test as appropriate was applied for the comparison of continuous variables between two groups and categorical variables were compared by chi-squared test or Fisher's exact test. Correlation between two continuous variables such as total duration of illness and duration of prior antibiotic intake was tested by Pearson's product moment correlation. Comparison of continuous variables between more than two groups was done by Kruskal-Wallis test. P-value less than 0.05 was considered statistically significant. All tests were two-sided.
Clinical features at presentation, in a study of 60 patients with blood culture-proven typhoid fever
Frequency, overall (n = 60)
NARST (n = 47)
NASST (n = 13)
MDR-ST (n = 22)
NonMDR-ST (n = 38)
Age, years *
15 ± 9
13 ± 9 †
23 ± 8 †
14 ± 9
16 ± 10
Fever, days ‡
10 (7–15) †
4 (3–6) †
27 (57) ∥
2 (15) ∥
All 60 isolates were sensitive to ciprofloxacin by disc diffusion testing and the MIC values of ciprofloxacin for all the isolates were within the susceptible range (0.016–1 μg/mL) as per current NCCLS definitions (susceptible if, MIC ≤ 1 μg/mL). Forty seven isolates (78%) were resistant to nalidixic acid (NARST) and the frequency of resistance to other antibiotics namely, chloramphenicol, amoxycillin and co-trimoxazole was 26 (43%), 28 (47%) and 30 (50%) respectively. About a third of isolates were MDR-ST (22 isolates, 37%) and no isolate was resistant to ceftriaxone (MIC range: 0.016–0.064 μg/mL; susceptible if, MIC ≤ 8 μg/mL).
Antibiotic susceptibility and clinical outcomes in a study of 60 patients with blood culture-proven typhoid fever
All patients (n = 60)
NARST (n = 47)
NASST (n = 13)
MDR-ST (n = 22)
NonMDR-ST (n = 38)
MIC ciprofloxacin, μg/mL
0.33 ± 0.21
0.37 ± 0.21*
0.17 ± 0.14*
0.37 ± 0.26
0.30 ± 0.18
MIC ceftriaxone, μg/mL
0.036 ± 0.016
0.038 ± 0.018
0.031 ± 0.01
0.033 ± 0.017
0.039 ± 0.016
Fever clearance time, days
5.1 ± 3.5
5.5 ± 3.8
3.7 ± 1.3
4.9 ± 2.7
5.3 ± 3.9
Total duration of illness, days
Haematological and biochemical findings in a study of 60 patients with blood culture-proven typhoid fever
Frequency, overall (n = 60)
NARST (n = 47)
NASST (n = 13)
MDR-ST (n = 22)
NonMDR-ST (n = 38)
AST > 2 × ULN
AST > 5 × ULN
ALT > 2 × ULN
ALT > 5 × ULN
Twenty six patients (43%) had received prior oral antibiotic therapy as outpatients, for a variable duration (2–17 days) before presentation: of which 11 patients (42%) had received fluoroquinolones for at least five days duration and thus were deemed to have clinical failure of fluoroquinolone therapy (others: cefixime – 7 patients [2–15 days]; ciprofloxacin – 4 patients [2–4 days]; amoxycillin – 3 patients [2–4 days]; azithromycin – 1 patient [2 days]). Among these 11 patients, three patients remained febrile even after 10 days of fluoroquinolone therapy. However, all the 11 isolates from patients with fluoroquinolone-failure were sensitive to ciprofloxacin in vitro, according to current NCCLS breakpoints (mean MIC: 0.34 ± 0.11 μg/mL; range: 0.125–0.5 μg/mL). Of the 11 instances of clinical failure of fluoroquinolone, in 10 patients the isolates were NARST.
The present study brings out the high frequency of nalidixic acid-resistance among S. typhi isolates from New Delhi, India. Moreover, this study reconfirms the occurrence of ciprofloxacin-susceptible but nalidixic acid-resistant S. typhi isolates and their relation to clinical failure of fluoroquinolone therapy. The frequency of nalidixic acid-resistance as found in the present study (78%) is high in comparison with earlier studies from India, in which it was in the range of 60–67% [13, 14]. However, it should be highlighted that these studies were temporally separated, hindering direct comparison between them. Being a hospital-based study, NARST strains might have been inadvertently overrepresented in the study population, since patients infected with NASST are more likely to be successfully treated in the community setting with fluoroquinolones. A community-based study is needed to estimate the actual proportion of infections caused by NARST. An earlier community-based prospective study conducted in New Delhi had found an alarmingly high rate of ciprofloxacin failure (9 out of 63 patients, 14%) as early as 1995–96 . In light of the consistent increase in the proportion of NARST isolates over the last decade, as suggested by data collected at our Institute , the high frequency of NARST strains as found in the present study seems to be a true phenomenon rather than due to selection bias. As documented in an earlier study conducted in south India , this increase in the frequency of NARST strains is associated with a consistent increase in the MIC levels of ciprofloxacin for S. typhi isolates .
Interesting is the fact that as per the current NCCLS breakpoints, these NARST isolates with higher MIC of ciprofloxacin would still be classified as being ciprofloxacin-susceptible. Notwithstanding, this subtle increase in the MIC of ciprofloxacin had an adverse impact on the clinical response to fluoroquinolone therapy: in the present study, all patients with clinical failure of fluoroquinolone therapy had isolates with MIC of ciprofloxacin ≤ 1 μg/mL. Hence, it is increasingly being felt that the common fluoroquinolone breakpoints for Enterobacteriaceae as set by the NCCLS, are to be reevaluated in the case of Salmonella species [13, 17, 18]. Currently, the NCCLS advises that testing of extraintestinal Salmonella isolates for nalidixic acid-resistance may be considered and that fluoroquinolone-susceptible strains of Salmonella that test resistant to nalidixic acid may be associated with clinical failure or delayed response in fluoroquinolone-treated patients with extraintestinal salmonellosis . In consonance with earlier studies [13, 20], the sensitivity of nalidixic acid-resistance as a surrogate marker for identifying isolates with increased levels of MIC of ciprofloxacin was found to be good in the present study. Thus, testing for nalidixic acid-resistance could be useful as a screening test for further determination of MIC levels of ciprofloxacin.
Since fluoroquinolones exhibit concentration-dependent killing, using higher doses of ciprofloxacin (750 mg b.i.d.) might compensate for this reduced susceptibility [7, 21]. Area under the curve (AUC) for serum concentrations attained with this dose is 19.2 ± 1.1 μg.h/mL . This extrapolates to an AUC/MIC ratio of about 77 in the case of half of the isolates encountered in the present study, which is well below the cut-off of > 250 that is required for rapid bactericidal action . Thus using higher doses of ciprofloxacin is also likely to prove ineffective in this population.
Higher frequency of hepatomegaly with greater elevation of hepatic enzymes and a trend for increased incidence of complications in patients with NARST isolates, all suggest that NARST is associated with severe clinical illness. Though the present study did not find a statistically significant association between NARST and the rate of complications, current findings strongly suggest that prior intake of antibiotics not capable of achieving fever clearance is associated with the development of complications. Thus it is reasonable to presume that the use of ciprofloxacin in populations where NARST is widely prevalent would delay the initiation of appropriate antibiotic therapy and thereby would lead to an excess of complications. The current observations are consistent with this hypothesis, though not confirmatory.
Earlier studies had reported that infection caused by MDR-ST was associated with more severe illness than non-MDR-ST infection [24, 25]. Noteworthy is the fact that in both these studies antibiotic used as first-line therapy was ampicillin/amoxycillin or chloramphenicol, to which MDR-ST is inherently resistant. Contrary to this, the present study and another study  using ciprofloxacin as first-line therapy found no significant differences between MDR-ST and non-MDR-ST infections. This analogy offers ancillary evidence in support of the hypothesis that using fluoroquinolones as first-line therapy in settings where NARST is prevalent, would result in poor outcomes. The other possibility is that development of drug resistance and virulence of the organism might be genetically linked. Blood bacterial counts were reported to be substantially higher in infections caused by MDR-ST than in infections caused by drug-susceptible S. typhi . A similar phenomenon is possible in the case of NARST also, accounting for poor outcomes. But the present study was not aimed at evaluating this possibility and this merits further study.
In this population, nalidixic acid-resistance is very common among isolates of S. typhi and is associated with reduced susceptibility to fluoroquinolones in vitro. Clinically this translates into frequent failure of fluoroquinolone therapy. However, this is not reflected in current NCCLS breakpoints and hence the fluoroquinolone breakpoints need to be redefined for S. typhi. Moreover, use of fluoroquinolones as first-line therapy for typhoid fever delays initiation of appropriate antibiotic in this setting and is likely to result in poor outcomes. For these reasons, fluoroquinolones should no longer be used as the first-line therapy, in populations where nalidixic acid-resistance is common among isolates of S. typhi.
We thank all Residents of the Departments of Medicine and Paediatrics and the laboratory staff of Bacteriology Laboratory, Department of Microbiology, All India Institute of Medical Sciences, for their kind help and cooperation.
- Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK: Typhoid fever in children aged less than 5 years. Lancet. 1999, 354: 734-737. 10.1016/S0140-6736(98)09001-1.View ArticlePubMedGoogle Scholar
- Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV: Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. 1998, 158: 633-638. 10.1001/archinte.158.6.633.View ArticlePubMedGoogle Scholar
- van den Bergh ET, Gasem MH, Keuter M, Dolmans MV: Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990. Trop Med Int Health. 1999, 4: 211-215. 10.1046/j.1365-3156.1999.43374.x.View ArticlePubMedGoogle Scholar
- Rowe B, Ward LR, Threlfall EJ: Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis. 1997, 24 (Suppl 1): S106-S109.View ArticlePubMedGoogle Scholar
- Threlfall EJ, Ward LR: Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg Infect Dis. 2001, 7: 448-450.View ArticlePubMedPubMed CentralGoogle Scholar
- Ackers ML, Puhr ND, Tauxe RV, Mintz ED: Laboratory-based surveillance of Salmonella serotype typhi infections in the United States – Anti-microbial resistance on the rise. JAMA. 2000, 283: 2668-2673. 10.1001/jama.283.20.2668.View ArticlePubMedGoogle Scholar
- Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ: Typhoid fever. N Engl J Med. 2002, 347: 1770-1782. 10.1056/NEJMra020201.View ArticlePubMedGoogle Scholar
- Bhat KG, Suresh K: Ciprofloxacin-resistant Salmonella typhi. Natl Med J India. 1999, 12: 88-PubMedGoogle Scholar
- Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S: Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet. 1999, 353: 1590-1591. 10.1016/S0140-6736(99)01001-6.View ArticlePubMedGoogle Scholar
- Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, Bhattacharya SK: Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res. 2001, 113: 210-213.PubMedGoogle Scholar
- Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NP, Solomon T, White NJ, Piddock LJ, Parry CM: Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997, 25: 1404-1410.View ArticlePubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. 2000, Wayne, PA: NCCLS, 7Google Scholar
- Kapil A, Renuka , Das B: Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi. Indian J Med Res. 2002, 115: 49-54.PubMedGoogle Scholar
- Rodrigues C, Mehta A, Joshi VR: Nalidixic acid-resistant Salmonella typhi in Mumbai. Natl Med J India. 1999, 12: 88-PubMedGoogle Scholar
- Renuka K, Kapil A, Kabra SK, Wig N, Das BK, Prasad VV, Chaudhry R, Seth P: Reduced susceptibility to ciprofloxacin and gyr-a gene mutation in North Indian strains of Salmonella enterica serotype Typhi and serotype Paratyphi A. Microb Drug Resist. 2004, 10: 146-153. 10.1089/1076629041310028.View ArticlePubMedGoogle Scholar
- Jesudason MV, Malathy B, John TJ: Trend of increasing levels of minimum inhibitory concentration of ciprofloxacin to Salmonella typhi. Indian J Med Res. 1996, 103: 247-249.PubMedGoogle Scholar
- Crump JA, Barrett TJ, Nelson JT, Angulo FJ: Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003, 37: 75-81. 10.1086/375602.View ArticlePubMedGoogle Scholar
- Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ: Is it time to change fluoroquinolone breakpoints for Salmonella spp.?. Antimicrob Agents chemother. 2003, 47: 827-829. 10.1128/AAC.47.2.827-829.2003.View ArticlePubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing: thirteenth informational supplement. NCCLS document M100-S13(M7). 2003, Wayne, PA: NCCLSGoogle Scholar
- Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P: Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol. 1999, 37: 3572-3577.PubMedPubMed CentralGoogle Scholar
- Slinger R, Desjardins M, McCarthy AE, Ramotar K, Jessamine P, Guibord C, Toye B: Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis. 2004, 4: 36-10.1186/1471-2334-4-36.View ArticlePubMedPubMed CentralGoogle Scholar
- Catchpole C, Andrews JM, Woodcock J, Wise R: The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother. 1994, 33: 103-110.View ArticlePubMedGoogle Scholar
- Schentag JJ, Meagher AK, Forrest A: Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother. 2003, 37: 1478-1488. 10.1345/aph.1C419.View ArticlePubMedGoogle Scholar
- Kabra SK, Madhulika , Talati A, Soni N, Patel S, Modi RR: Multidrug-resistant typhoid fever. Trop Doct. 2000, 30: 195-197.PubMedGoogle Scholar
- Bhutta ZA: Impact of age and drug resistance on mortality in typhoid fever. Arch Dis Child. 1996, 75: 214-217.View ArticlePubMedPubMed CentralGoogle Scholar
- Alsoub H, Uwaydah AK, Matar I, Zebeib M, Elhag KM: A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Br J Clin Pract. 1997, 51: 8-10.PubMedGoogle Scholar
- Wain J, Diep TS, Ho VA, Walsh AM, Nguyen TT, Parry CM, White NJ: Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol. 1998, 36: 1683-1687.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/5/37/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.